Femasys Inc(FEMY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.62 | Insider Own | 3.43% | Shs Outstand | 8.4M | Perf Week | -3.32% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 18.27% | Insider Trans | 17.06% | Shs Float | 8.1M | Perf Month | -34.5% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.6 | Inst Own | 52.64% | Short Float | 2.03% | Perf Quarter | -50.75% |
| Income | -0.01B | P/S | 4.77 | EPS this Y | 72.34% | Inst Trans | 33.6% | Short Ratio | 0.23 | Perf Half Y | -85.42% |
| Sales | 0.00B | P/B | 0.98 | EPS next 5Y | 44.87% | ROA | -94.25% | Short Interest | 0.16M | Perf YTD | -88.63% |
| Book/sh | 1.33 | P/C | 7.62 | EPS past 3/5Y | 21.27% 4.34% | ROE | -443.65% | 52W High | -94.1% ($22.20) | Perf Year | -92.16% |
| Cash/sh | 0.17 | P/FCF | - | Sales past 3/5Y | 23.88% 17.18% | ROIC | -147.17% | 52W Low | 1.55% ($1.29) | Perf 3Y | -95.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.27% | Gross Margin | 25.45% | Volatility(W/M) | 9.53% 11.13% | Perf 5Y | -99.1% |
| Dividend TTM | - | EV/Sales | 6.23 | Sales Y/Y TTM | 21.86% | Oper. Margin | -763.9% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.55 | EPS Q/Q | 58.08% | Profit Margin | -534.27% | RSI (14) | 30.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.14 | Sales Q/Q | -18.92% | SMA20 | -15.07% ($1.54) | Beta | -2.17 | Target Price | $16.5 |
| Payout | - | Debt/Eq | 1.19 | Earnings | 2026/8/14 | SMA50 | -39.42% ($2.16) | Rel Volume | 0.15 | Prev Close | $1.44 |
| Employees | 54 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | -1.53% -54.59% | SMA200 | -77.79% ($5.9) | Avg Volume(3M) | 0.73M | Price | $1.31 |
| IPO | 2021/6/18 | Option/Short | No/Yes | Trades | 647 | Volume | 109,874 | Change | -9.03% |
Femasys is a women's health medical device company pursuing FDA approval for FemBloc, the world's first non-surgical permanent contraceptive device. The company develops and sells reproductive health products for women, including FemaSeed (intrauterine insemination) and FemVue (fallopian tube diagnosis), and European commercialization has begun.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded less than usual. That is 15% of its average volume.
FEMY has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +72.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $477. Peers typically go for $246.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 52.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #48 of 51 in the industry
Based on market cap of $11M.
FAQ
What kind of company is FEMY?
FEMY belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of FEMY?
The market cap of FEMY is approximately $11M, ranking 5,382 within its sector.
What is the 52-week high and low for FEMY?
FEMY has recorded a 52-week high of $22.20 and a low of $1.29.
